GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » FCF Yield %

Neuraxis (Neuraxis) FCF Yield % : -35.62 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Neuraxis's Trailing 12-Month Free Cash Flow is $-7.48 Mil, and Market Cap is $21.01 Mil. Therefore, Neuraxis's FCF Yield % for today is -35.62%.

The historical rank and industry rank for Neuraxis's FCF Yield % or its related term are showing as below:

NRXS' s FCF Yield % Range Over the Past 10 Years
Min: -57.74   Med: -36.26   Max: -6.42
Current: -35.62


During the past 4 years, the highest FCF Yield % of Neuraxis was -6.42%. The lowest was -57.74%. And the median was -36.26%.

NRXS's FCF Yield % is ranked worse than
69.95% of 1554 companies
in the Biotechnology industry
Industry Median: -14.415 vs NRXS: -35.62

Neuraxis's FCF Margin % for the quarter that ended in Mar. 2024 was -208.19%.


Neuraxis FCF Yield % Historical Data

The historical data trend for Neuraxis's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis FCF Yield % Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - - -38.93

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -58.44 -60.90 -26.19

Competitive Comparison of Neuraxis's FCF Yield %

For the Biotechnology subindustry, Neuraxis's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Neuraxis's FCF Yield % falls into.



Neuraxis FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Neuraxis's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-6.766 / 17.378763
=-38.93%

Neuraxis's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.347 * 4 / 20.576088
=-26.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Neuraxis FCF Yield % Related Terms

Thank you for viewing the detailed overview of Neuraxis's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis (Neuraxis) Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042